Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare the efficacy of continuous every 2-week (Q2W) dosing versus continuous every 4-week (Q4W) dosing of ixekizumab in the treatment of patients with moderate-to-severe plaque psoriasis (Ps), as measured by static Physician Global Assessment (sPGA) (0,1) and PASI 75 (75% improvement from baseline in the Psoriasis Area and Severity Index).
Critère d'inclusion
- Moderate to Severe Plaque Psoriasis